ImmunoGen IncNASDAQ:IMGN
- LAST PRICE2.49
- TODAY'S CHANGE (%)0.01 (0.40%)
- Bid / Lots2.48/ 20
- Ask / Lots2.49/ 2
- Open / Previous Close2.50 / 2.48
- Day Range
- 52 Week Range
- Volume758,720
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | IMGN |
|---|---|---|
| 09:32 ET | 6554 | 2.48 |
| 09:34 ET | 101 | 2.47 |
| 09:36 ET | 16250 | 2.48 |
| 09:38 ET | 457 | 2.5 |
| 09:39 ET | 6805 | 2.49 |
| 09:41 ET | 8642 | 2.51 |
| 09:43 ET | 1250 | 2.5 |
| 09:45 ET | 2238 | 2.5 |
| 09:48 ET | 900 | 2.52 |
| 09:50 ET | 500 | 2.53 |
| 09:52 ET | 2209 | 2.52 |
| 09:54 ET | 4900 | 2.52 |
| 09:56 ET | 8424 | 2.51 |
| 09:57 ET | 100 | 2.51 |
| 09:59 ET | 600 | 2.51 |
| 10:01 ET | 2100 | 2.5 |
| 10:03 ET | 100 | 2.51 |
| 10:06 ET | 1250 | 2.51 |
| 10:08 ET | 1619 | 2.51 |
| 10:10 ET | 400 | 2.51 |
| 10:12 ET | 1537 | 2.51 |
| 10:14 ET | 200 | 2.51 |
| 10:15 ET | 1300 | 2.51 |
| 10:17 ET | 280 | 2.51 |
| 10:19 ET | 6170 | 2.52 |
| 10:21 ET | 427 | 2.52 |
| 10:24 ET | 2161 | 2.52 |
| 10:26 ET | 3700 | 2.53 |
| 10:28 ET | 5500 | 2.52 |
| 10:30 ET | 200 | 2.52 |
| 10:32 ET | 5991 | 2.51 |
| 10:33 ET | 200 | 2.51 |
| 10:35 ET | 1300 | 2.5 |
| 10:37 ET | 2330 | 2.51 |
| 10:39 ET | 1400 | 2.51 |
| 10:42 ET | 19771 | 2.51 |
| 10:44 ET | 700 | 2.5 |
| 10:46 ET | 1200 | 2.5 |
| 10:48 ET | 2260 | 2.51 |
| 10:50 ET | 7038 | 2.5 |
| 10:51 ET | 600 | 2.5 |
| 10:53 ET | 1300 | 2.49 |
| 10:55 ET | 959 | 2.5 |
| 10:57 ET | 2800 | 2.49 |
| 11:00 ET | 100 | 2.49 |
| 11:02 ET | 12687 | 2.49 |
| 11:04 ET | 3400 | 2.48 |
| 11:06 ET | 4449 | 2.48 |
| 11:08 ET | 2500 | 2.49 |
| 11:09 ET | 1500 | 2.49 |
| 11:11 ET | 900 | 2.49 |
| 11:13 ET | 26215 | 2.49 |
| 11:15 ET | 800 | 2.48 |
| 11:18 ET | 600 | 2.48 |
| 11:20 ET | 2190 | 2.48 |
| 11:22 ET | 3279 | 2.47 |
| 11:24 ET | 6797 | 2.48 |
| 11:26 ET | 400 | 2.48 |
| 11:27 ET | 3460 | 2.48 |
| 11:29 ET | 300 | 2.48 |
| 11:31 ET | 2500 | 2.48 |
| 11:33 ET | 800 | 2.49 |
| 11:36 ET | 1600 | 2.48 |
| 11:38 ET | 3200 | 2.48 |
| 11:40 ET | 800 | 2.48 |
| 11:42 ET | 7700 | 2.47 |
| 11:44 ET | 2366 | 2.47 |
| 11:45 ET | 11552 | 2.47 |
| 11:47 ET | 2855 | 2.46 |
| 11:49 ET | 2000 | 2.46 |
| 11:51 ET | 1772 | 2.46 |
| 11:54 ET | 2800 | 2.46 |
| 11:56 ET | 314 | 2.47 |
| 11:58 ET | 2200 | 2.47 |
| 12:00 ET | 1400 | 2.47 |
| 12:02 ET | 500 | 2.46 |
| 12:03 ET | 4602 | 2.46 |
| 12:05 ET | 1635 | 2.46 |
| 12:07 ET | 609 | 2.47 |
| 12:09 ET | 2200 | 2.47 |
| 12:12 ET | 100 | 2.46 |
| 12:14 ET | 3415 | 2.47 |
| 12:16 ET | 1701 | 2.47 |
| 12:18 ET | 1236 | 2.47 |
| 12:20 ET | 4892 | 2.46 |
| 12:21 ET | 1200 | 2.46 |
| 12:23 ET | 500 | 2.47 |
| 12:25 ET | 2600 | 2.46 |
| 12:27 ET | 900 | 2.46 |
| 12:30 ET | 1750 | 2.46 |
| 12:32 ET | 1280 | 2.46 |
| 12:34 ET | 5525 | 2.47 |
| 12:36 ET | 1400 | 2.48 |
| 12:38 ET | 1000 | 2.47 |
| 12:39 ET | 500 | 2.47 |
| 12:41 ET | 2417 | 2.47 |
| 12:45 ET | 2600 | 2.47 |
| 12:48 ET | 1725 | 2.46 |
| 12:50 ET | 400 | 2.47 |
| 12:52 ET | 850 | 2.46 |
| 12:54 ET | 400 | 2.46 |
| 12:56 ET | 794 | 2.47 |
| 12:57 ET | 600 | 2.46 |
| 12:59 ET | 500 | 2.46 |
| 01:01 ET | 500 | 2.47 |
| 01:03 ET | 600 | 2.47 |
| 01:06 ET | 5460 | 2.46 |
| 01:08 ET | 2700 | 2.46 |
| 01:10 ET | 400 | 2.46 |
| 01:12 ET | 500 | 2.46 |
| 01:14 ET | 100 | 2.46 |
| 01:15 ET | 500 | 2.46 |
| 01:19 ET | 1257 | 2.46 |
| 01:21 ET | 700 | 2.46 |
| 01:24 ET | 500 | 2.46 |
| 01:26 ET | 200 | 2.46 |
| 01:28 ET | 1800 | 2.46 |
| 01:30 ET | 400 | 2.46 |
| 01:32 ET | 1000 | 2.47 |
| 01:33 ET | 400 | 2.46 |
| 01:35 ET | 560 | 2.47 |
| 01:37 ET | 614 | 2.47 |
| 01:39 ET | 100 | 2.46 |
| 01:42 ET | 4378 | 2.46 |
| 01:44 ET | 7208 | 2.46 |
| 01:46 ET | 400 | 2.46 |
| 01:48 ET | 300 | 2.46 |
| 01:50 ET | 800 | 2.46 |
| 01:51 ET | 300 | 2.46 |
| 01:53 ET | 1600 | 2.47 |
| 01:55 ET | 3635 | 2.46 |
| 01:57 ET | 3300 | 2.46 |
| 02:00 ET | 4952 | 2.47 |
| 02:02 ET | 4100 | 2.48 |
| 02:04 ET | 5700 | 2.48 |
| 02:06 ET | 14023 | 2.48 |
| 02:08 ET | 1600 | 2.48 |
| 02:09 ET | 600 | 2.48 |
| 02:11 ET | 1250 | 2.48 |
| 02:13 ET | 900 | 2.48 |
| 02:15 ET | 590 | 2.49 |
| 02:18 ET | 6450 | 2.49 |
| 02:20 ET | 1100 | 2.49 |
| 02:22 ET | 300 | 2.5 |
| 02:24 ET | 7544 | 2.49 |
| 02:26 ET | 1762 | 2.49 |
| 02:27 ET | 200 | 2.49 |
| 02:29 ET | 1200 | 2.49 |
| 02:31 ET | 1630 | 2.5 |
| 02:33 ET | 1100 | 2.49 |
| 02:36 ET | 1600 | 2.49 |
| 02:38 ET | 399 | 2.5 |
| 02:40 ET | 100 | 2.49 |
| 02:42 ET | 3109 | 2.49 |
| 02:44 ET | 16368 | 2.5 |
| 02:45 ET | 13549 | 2.49 |
| 02:47 ET | 19914 | 2.49 |
| 02:49 ET | 11891 | 2.48 |
| 02:51 ET | 1000 | 2.48 |
| 02:54 ET | 1200 | 2.48 |
| 02:56 ET | 1066 | 2.48 |
| 02:58 ET | 1627 | 2.48 |
| 03:00 ET | 200 | 2.49 |
| 03:02 ET | 1890 | 2.49 |
| 03:03 ET | 1335 | 2.48 |
| 03:05 ET | 800 | 2.48 |
| 03:07 ET | 3000 | 2.48 |
| 03:09 ET | 1100 | 2.48 |
| 03:12 ET | 2437 | 2.48 |
| 03:14 ET | 1315 | 2.49 |
| 03:16 ET | 1700 | 2.48 |
| 03:18 ET | 1600 | 2.48 |
| 03:20 ET | 1405 | 2.48 |
| 03:21 ET | 1872 | 2.48 |
| 03:23 ET | 650 | 2.49 |
| 03:25 ET | 300 | 2.48 |
| 03:27 ET | 760 | 2.49 |
| 03:30 ET | 800 | 2.48 |
| 03:32 ET | 700 | 2.48 |
| 03:34 ET | 900 | 2.48 |
| 03:36 ET | 11831 | 2.48 |
| 03:38 ET | 600 | 2.48 |
| 03:39 ET | 1500 | 2.48 |
| 03:41 ET | 600 | 2.48 |
| 03:43 ET | 1000 | 2.48 |
| 03:45 ET | 3395 | 2.48 |
| 03:48 ET | 11778 | 2.49 |
| 03:50 ET | 1090 | 2.49 |
| 03:52 ET | 16781 | 2.49 |
| 03:54 ET | 2100 | 2.48 |
| 03:56 ET | 20071 | 2.48 |
| 03:57 ET | 12232 | 2.48 |
| 03:59 ET | 122169 | 2.49000000953674 |
Sep 30, 2019
ImmunoGen Says Drug Combination in Study Showed Anti-Tumor Activity in Ovarian Cancer Patients
Sep 29, 2019
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin(R) at ESMO
ImmunoGen Presents Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine in Ovarian Cancer at ESMO
Sep 19, 2019
BUZZ-U.S. STOCKS ON THE MOVE-Applied DNA, United States Steel, Overstock.com, Eros International
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
ImmunoGen Inc | 371.7M | --- | --- |
Predictive Technology Group Inc | 379.2M | --- | --- |
Lexicon Pharmaceuticals Inc | 351.8M | --- | --- |
Personalis Inc | 374.2M | --- | --- |
CytomX Therapeutics Inc | 317.9M | --- | --- |
Agenus Inc | 357.0M | --- | --- |
Company Information
ImmunoGen, Inc. is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its product candidates include Mirvetuximab soravtansine; IMGN779; IMGN632; and Coltuximab ravtansine. Its portfolio is led by Mirvetuximab soravtansine, a first-in-class ADC targeting folate-receptor alpha (Fra), which is in a Phase III registrational trial called FORWARD I. Its FORWARD II trial consists of cohorts assessing Mirvetuximab soravtansine in combination with Avastin (bevacizumab), Keytruda (pembrolizumab) and carboplatin. The Company has developed tubulin-acting maytansinoid payload agents, which include DM1 and DM4, as well as deoxyribonucleic acid (DNA)-alkylating agents called IGNs.
Contact Information
- Headquarters
- 830 WINTER STWALTHAM, MA, United States 02451-1477
- Phone
- 781-895-0600
- Fax
- 781-895-0611
Executives
- Independent Chairman of the Board
- Stephen McCluski
- President, Chief Executive Officer, Director
- Mark Enyedy
- Executive Vice President, General Counsel, Secretary
- Craig Barrows
- Executive Vice President and Chief Business Officer
- Blaine Mckee
- Senior Vice President and Chief Medical Officer
- Anna Berkenblit
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $371.7M |
|---|---|
Revenue (TTM) | $48.5M |
Shares Outstanding | 149.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | 0.00 USD |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 2.18 |
EPS | $-1.19 |
Book Value | $0.07 |
P/E Ratio | --- |
Price/Sales (TTM) | 7.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -347.97% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
